BVSBioventus Inc - Ordinary Shares - Class A
$9.05
$0.15
(1.63%)
Closed $9.05
$0.00
(0.00%)
After Hours
EarningsAug 4
Mkt Cap$768.52M
Vol400,695.00
Fundamentals
Mkt Cap
$768.52M
Volume
-
52W High
$11.25
52W Low
$5.81
PE Ratio
21.96
Avg. Volume
627,841.67
EPS (Annual)
$0.3299
Rev/Employee
$610,846.24
Earnings
Aug 04
39
Bearish Sentiment
How do you feel about BVS?
Are Investors Undervaluing Bioventus (BVS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.
Zacks
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS)
The heavy selling pressure might have exhausted for Bioventus (BVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts PR Newswire TAMPA, Fla., June 2, 2026 Issued on behalf of Conexeu Sciences Inc.A newly listed...
PR Newswire
Transcript: Bioventus Q1 2026 Earnings Conference Call
read more...
Benzinga
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Bioventus (BVS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It PR Newswire NEW YORK, May 22, 2026 Issued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ...
PR Newswire
Is Bioventus (BVS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Here is how Bioventus (BVS) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.
Zacks
Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High?
The consensus price target hints at a 39% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
<
1
2
...
>